Summary
- Investor Relations can make an uninitiated investor think a biotechnology is better than it is.
- Publication of peer-reviewed, original research is how investigators in medical science prove themselves.
- Most articles discussing biotechnology in Seeking Alpha neglect the bibliography of Scientific Officers and thus neglect to review evidence of what drives a company's biotechnology.
I searched Google Scholar for all peer-reviewed scientific publications of Chief Scientific or Medical Officers of 3 groups of biotechnology companies: the 1st group was comprised of Jim Cramer's four horseman, a title referring to Biogen (NASDAQ:BIIB), Celgene (NASDAQ:CELG), Gilead (NASDAQ:GILD), and Regeneron (NASDAQ:REGN); the 2nd group was comprised by 4 small cap biotechs I own with hefty price appreciations over the past 6 months: bluebird bio (NASDAQ:BLUE) up 70%, Cellectis (OTCPK:CMVLF) up 134%, Seattle Genetics (NASDAQ:SGEN) up 43%, and Sorrento (NASDAQ:SRNE) up 65% in the past 6 months; the 3rd group comprised by 4 small cap biotechs I have owned or still own with 6-month price depreciation: AEterna Zentaris (NASDAQ:AEZS) down 56%, Benitec (OTCPK:BNIKF) down 32%, Vical (NASDAQ:VICL) down 35%, and Transgenomics (NASDAQ:TBIO) down 20% in the past 6 months.
Company | Ticker | Chief Scientist | Journal 1st authorships | Top Journals |
Biogen | BIIB | Spyros Artavanis-Tsakonas | 9 | Cell; Proceedings of the National Academy of Science; Science |
Celgene | CELG | Thomas O. Daniel | 6 | PNAS; Kidney International |
Gilead | GILD | Norbert W. Bischofberger | 17 | J. Am. Chemical Soc.; J. Organic Chem.; Nucleic Acid Research |
Regeneron | REGN | George D. Yancopoulos | 12 | Cell; Nature; PNAS |
The most impressive bibliography, in my opinion, belongs George D. Yancopoulos who has been with Regeneron since 1989 and who has a dozen 1st authorships including one in Nature, two in Cell, and two in Proceedings of the National Academy of Science. Regeneron's wesbsite modestly lists only the most recent of its scientists publications, four of which are in New England Journal of Medicine, one in PNAS. And look at how his company's stock has performed:
(click to enlarge)
Nearly as impressive is Biogen's CSO, Spyros Artavanis-Tsakonas, formerly of Department Of Cell Biology, Harvard Medical School. I found nine 1st authorships including two in the journal Science, one in PNAS, and one in Cell. I think most clinician scientists would tell you they would be satisfied with their research careers if they had even one publication in one of these journals!
Celgene likewise lists only a few select publications, and only those relating to Cell Therapy program - I found this section of the CELG website interesting because I know CELG best for its profitable myeloma franchise, not for cell therapy. Celgene's R&D President is Thomas O. Daniel: I found six 1st authorships mostly in journals of nephrology which is his medical subspecialty.
Gilead's Norbert W. Bischofberger is another former Harvard professor. The 1st authorships I found in Google Scholar were in peer-reviewed biochemical journals.
Company | Ticker | Chief Scientist | Journal 1st authorships | Top Journals |
bluebird | BLUE | Philip D Gregory | 8 | Cell; Nature;PNAS |
Cellectis | CMVLF | Philippe Duchateau | 5 | J Biol. Chem.; J Lipid Res.; Molecular Therapy |
Seattle Genetics | SGEN | Jonathan Drachman | 11 | PNAS; Blood; J Biol Chem |
Sorrento | SRNE | NONE | N/A | N/A |
I then searched the bibiography of Oxford BioMedica's CSO "Kyriacos Mitrophanous" and did not find a single 1st authorship on a peer-reviewed research publication. This is not to impune his career - he has been part of research teams that published results in good journals, but I do not find the bibliography of a world-class scientist in his - but I do in his "rival" who is now at bluebird bio. But if you read the SA article by EP Advantage you might come away with the mistaken notion that these two companies are comparable except in stock price which is just not true.
Company | Ticker | Chief Scientist | Journal 1st authorships | Top Journals |
AEterna Zentaris | AEZS | Richard Sachse | 3 | Oncogene, Eur. J. Endo. |
Benitec | BNIKF | David Suhy | 8 | Molecular Therapy; J Virology; J Biol Chem. |
Transgenomics | TBIO | NONE | N/A | N/A |
Vical* | VICL | Mammen P. Mammen | 2 | PLoS Med; Clin. Infectious Dis. |
Conclusions: there is certainly more to learn about a biotechnology than you can get by just looking at the bibliography of the chief scientist. You can look for publications at the company website and read some of them. I routinely scan the New England Journal of Medicine looking for important new therapies. For example, about the same time Gilead stock began its decline after the Waxman letter to congress, two articles about Idelalisib appeared in New England Journal of Medicine here and here - those simultaneous events were a strong BUY signal.
When I look at the bibliography of Regeneron's chief scientist, I find it extremely compelling, and it sets the bar for other biotech stocks I consider buying. When I look at the research accomplishments of the Chief Medical Officer for SGEN, it gives me confidence to own that stock as it appreciates to become one of my top holdings; same for BLUE. Absence of a chief scientific or medical officer in Sorrento's leadership, something I overlooked when I purchased, now gives me significant concern. When I look at the bibliographies of the CSOs of the 4 companies in the 3rd table, I now see a possible basis for their underperformance, Benitec excepted - I think David Suhey is doing some excellent research for this very small Australian biotech. To the contrary I now see TBIO as a SELL.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
No comments:
Post a Comment